Skip to main content
. 2022 Sep 6;2022:7255331. doi: 10.1155/2022/7255331

Table 3.

Regression analysis of FA supplementation with HDCP and preeclampsia (nonusers group as reference).

Nonuser User
Non-FA (n = 1028) Early pregnancy Whole pregnancy
0.4 FA (n = 4321) MV + 0.4 FA (n = 831) MV + 0.8 FA (n = 2309) 0.4 FA (n = 838) MV + 0.4 FA (n = 418) MV + 0.8 FA (n = 917)
HDCP
Crude RR (95% CI) 1 0.71(0.49-1.05) 0.75 (0.44-1.28) 0.42 (0.27-0.68) 0.64(0.36-1.12) 0.68 (0.33-1.37) 0.49 (0.27-0.89)
P 0.084 0.294 0.001 0.120 0.279 0.019
Model RR (95% CI) 1 0.82(0.55-1.20) 0.93 (0.54-1.61) 0.49 (0.31-0.80) 0.77(0.43-1.35) 0.80 (0.39-1.65) 0.62 (0.34-1.15)
P 0.305 0.789 0.004 0.358 0.553 0.128

Preeclampsia
Crude RR (95% CI) 1 0.52(0.28-0.99) 0.70 (0.29-1.69) 0.09 (0.03-0.33) 0.44(0.16-1.21) 0.70 (0.23-2.14) 0.40 (0.14-1.11)
P 0.046 0.431 0.001 0.111 0.531 0.077
Model RR (95% CI) 1 0.61(0.32-1.16) 0.88 (0.36-2.16) 0.11 (0.03-0.39) 0.53(0.19-1.49) 0.84 (0.27-2.62) 0.53 (0.19-1.50)
P 0.132 0.787 0.001 0.227 0.766 0.23

Crude: without adjusting for any covariates. Model: adjusted for education, prepregnancy BMI, age, weight gain during pregnancy, ethnicity, infant gender, and primiparity. FA: folic acid, 0.4 FA: 0.4 mg folic acid, MV + 0.4 FA: multivitamins with 0.4 mg folic acid, MV + 0.8 FA: multivitamins with 0.8 mg folic acid. P < 0.05.